How is the needle moving on this healthcare Stock:BioDelivery Sciences International, Inc.(NASDAQ: BDSI)
BioDelivery Sciences International Inc (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.
Highlights:
Dec. 20, 2021, Company announced that the U.S. District Court of Delaware has issued an opinion in favor of BDSI in the company’s patent litigation against Alvogen Group, Inc. and its affiliates, who filed an Abbreviated New Drug Application (ANDA) for BDSI’s BELBUCA® product.
Recent Acquisition – Closed acquisition of ELYXYB on September 9, 2021, the first FDA-approved, ready-to-use oral solution for acute migraine with potential long-term peak sales opportunity of $350 – $400 million. The acquisition talk with Collegium can also provide a boost to stock price
Strong Q3 numbers- Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year, Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million Operating Cash Flow. Quick look at last 5 quarterly numbers
Increased Sales –Net sales of BELBUCA® and Symproic® combined grew 7.5% year-over-year. This growth was driven by record BELBUCA net sales of $36.9 million, which increased 6.3%, and Symproic net sales of $4.1 million, which increased 20%.
Improved EPS- last 3 Quarters out of 4, company has been reporting higher EPS than estimated, Q2 2021 EPS reported was 80% higher than estimated.
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Earnings Per Share* | Consensus EPS* Forecast | % Surprise |
| Sep 2021 | 11/03/2021 | 0.07 | 0.06 | 16.67 |
| Jun 2021 | 08/04/2021 | 0.09 | 0.05 | 80 |
| Mar 2021 | 05/06/2021 | 0.05 | 0.07 | -28.57 |
| Dec 2020 | 03/10/2021 | 0.1 | 0.06 | 66.67 |
Quick Look at Company’s Key Data
In fiscal Year 2021 company shares have shown annual returns of around 30%. Last 1 Year Chart
Stock Recommendation: The company is on track for its second profitable year. Company is also set to launch a migraine treatment this quarter. Acquisition talk with Collegium & current market positivity in healthcare sector can also provide a boost to stock price
MarketFacts gives a “Buy” rating on the stock at the closing Price of $3.0 as of January 18th, 2022.
| CMP (USD) (18th Jan 2022) | $3.0 |
| Target Price (CAD) | $4.25 |
| Recommendation | Buy |
